Brivaracetam
Prescription anti-epileptic medicine for focal seizures; it belongs to the racetam family but is not a lifestyle nootropic.
Pharmacology
Contents
DETAILED OVERVIEW
What is Brivaracetam?
Brivaracetam (brand name Briviact) is a prescription anti-epileptic medicine, approved in 2016 in the United States and the EU to treat focal, that is partial-onset, seizures. In the United States it is a controlled substance with a low risk of misuse (Schedule V). Chemically it belongs to the racetam family, but it is a serious medicine, not a lifestyle nootropic.
It binds to a brain protein called SV2A that takes part in signaling between nerve cells, more strongly than the related levetiracetam, and so reduces the excessive release of messenger substances that triggers seizures. Its effect starts quickly, and several large placebo-controlled studies have confirmed it. The most common side effects are drowsiness, dizziness and tiredness; irritability, anxiety, depression and aggression can also occur, and the prescribing information warns about suicidal thoughts, as for other anti-epileptic drugs. Stopping it suddenly can trigger seizures, and together with alcohol its sedating effect adds up.
Mechanism
Selective high-affinity SV2A ligand
Half-life
~9 h
Onset
~1 h (fast CNS entry)
Legal status
Rx (FDA/EMA); US Schedule V
Unlike piracetam-type racetams, brivaracetam is discussed mainly in a clinical context rather than as a community nootropic, because it is a prescription antiepileptic and a controlled substance. Patients on it for focal epilepsy sometimes report improved alertness or mood once seizures are better controlled, but this is confounded by the underlying condition and by switching from other drugs. There is no established off-label nootropic protocol, and the SV2A mechanism does not produce the acute, feelable cognitive push people associate with stimulant racetams. Any interest in its cognitive or neuroprotective angle remains at the research stage and should be pursued only under medical supervision.
⚠ Not clinical evidence – based on user accounts.
Receptor profile
- SV2A synaptic vesicle proteinStrong
- Presynaptic neurotransmitter releaseModerate
- Neuronal voltage-gated sodium channelsWeak
Safety
Side effects, stop signs, contraindications
Side effects · 6
- Somnolence and sedation, the most common adverse effect, especially early in treatment
- Dizziness and balance disturbance, dose-dependent
- Fatigue and lethargy
- Nausea and vomiting, mild gastrointestinal discomfort
- Psychiatric and behavioral reactions: irritability, anxiety, depression, aggression
- Coordination difficulties and unsteady gait, at higher doses
Contraindications · 6
- Hypersensitivity to brivaracetam or levetiracetam
- Pregnancy and breastfeeding: limited data, only under specialist supervision
- Suicidal ideation or psychiatric history: antiepileptic class warning, close monitoring
- Hepatic impairment: dose reduction required (hepatic metabolism)
- Do not stop abruptly: withdrawal seizure risk, gradual tapering is required
- Alcohol and CNS depressants: additive sedation and psychomotor impairment
Related Nootropics
Same therapeutic category
Studies
Related research and clinical findings
Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity.
Kenda BM, Matagne AC, Talaga PE, et al.
Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
Nicolas JM, Hannestad J, Holden D, et al.
Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial.
Ryvlin P, Werhahn KJ, Blaszczyk B, et al.
Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial.
Kwan P, Trinka E, Van Paesschen W, et al.
Brivaracetam add-on therapy for drug-resistant epilepsy.
Bresnahan R, Panebianco M, Marson AG.
Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model.
Kasteleijn-Nolst Trenite DG, Genton P, Parain D, et al.
FAQ
FAQ
Brivaracetam is a prescription, officially approved medication used to reduce the frequency of epileptic seizures, specifically focal (partial-onset) seizures, either alone or alongside other medications. It acts quickly and is generally well tolerated compared to older similar drugs. Researchers are also looking into possible neuroprotective and cognitive effects, but that's still research interest, not an approved use.
Telegram
Have a question about Brivaracetam?
Reach out to us on Telegram for a personalized stack. We'll be happy to help.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
Structure & chemistry
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.